Risk of hematological adverse events with the use of immune checkpoint inhibitors
Not Applicable
- Conditions
- Solid tumors
- Registration Number
- JPRN-UMIN000046032
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Please refer to the following: https://www.thejh.org/index.php/jh/article/view/1090/715
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20033
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to adverse events listed in inclusion criteria. (6) Studies with no or insufficient safety results at the time of the literature search. (7) Studies published in languages other than English. Two investigators independently screened all titles, abstracts, and full texts for eligibility. Final inclusion will be decided after resolving discrepancies between the two investigators.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The odds ratio (OR) of any grade hematological AEs will be calculated. Meta-analysis will be performed to compare the incidence of hematological AEs between ICI-containing arm and control arm.
- Secondary Outcome Measures
Name Time Method The frequency of hematological AEs will be pooled using random-model meta-analysis.